Q-omics provides the consensus-scored GRM2 profile across patient tissues and cancer cell-line models. GRM2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GRM2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, GRM2 RNA expression shows 17,895 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, HNSC, and TGCT as cancer lineages where GRM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRM2 survival associations across molecular data types. GRM2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRM2 RNA expression–survival associations across cancer types. High GRM2 expression shows unfavorable associations in MESO, THCA, ACC and KIRP, but favorable associations in UCEC and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for GRM2 RNA expression.
This table summarizes GRM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GRM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRM2 shows lower tumor expression in KIRP and higher tumor expression in HNSC, COAD, UCEC, LIHC and BRCA. The HNSC box plot shows higher GRM2 RNA expression in tumor versus normal tissue (log2 FC = +0.189, t-test p < 0.001).
This table shows molecular features associated with GRM2 in patient tissues and cancer cell lines. In patient samples, GRM2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GRM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
